-
FDA emphasises need for adverse event reporting of compounded drugs
europeanpharmaceuticalreview
September 16, 2019
The FDA says that even though it recognises the importance of compounded drugs, they also pose a risk to patient safety.
-
New drug may protect against memory loss in Alzheimer's disease
worldpharmanews
September 10, 2019
A new drug discovered through a research collaboration between the University at Buffalo and Tetra Therapeutics may protect against memory loss...
-
Federal judge enters consent decree against drug distributors
europeanpharmaceuticalreview
September 10, 2019
Two Tennessee companies have been prevented from distributing drugs after a complaint they were supplying unapproved medications.
-
Cyxone Explores Orphan Drug Designation for Rabeximod
americanpharmaceuticalreview
September 09, 2019
Cyxone announced the company's board of directors has decided to explore the possibilities of an orphan drug designation (ODD) of the drug candidate Rabeximod.
-
Underused Drug Combo May Up Survival in Lung Transplant
drugs
September 06, 2019
A little used immunosuppression regimen may substantially improve survival following lung transplant, according to a study published online in JAMA Network Open.
-
Drug delivery improved through mesoporous materials
europeanpharmaceuticalreview
September 06, 2019
A new study on DOX as a model drug has potential applications in the drug delivery field for better control drug release.
-
Cidara and Mundipharma sign rezafungin drug development deal
pharmaceutical-technology
September 05, 2019
US-based biotech Cidara Therapeutics has partnered with UK-based Mundipharma in a deal valued at more than $568m to develop and commercialise its anti-fungal drug rezafungin.
-
Experimental validation confirms the ability of artificial intelligence to accelerate drug discovery
worldpharmanews
September 05, 2019
Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification of potent DDR1 kinase inhibitors," in Nature Biotechnology.
-
Brain disease drug delivery platform developed by researchers
europeanpharmaceuticalreview
September 05, 2019
So-called ‘nanodiamonds’ could serve as a platform for diagnostic and therapeutic approaches for neurodegenerative diseases.
-
Experimental Drug Works Quickly on Major Depression
drugs
September 05, 2019
Antidepressants typically take four to eight weeks to ease the debilitating symptoms of depression, but an early clinical trial found a new type of drug brought relief in just two weeks.